trial

Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia

NCTId NCT05964790
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Unknown
Enrollment 112 (estimated)
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Primary completion 2024-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Unknown
Enrollment
112 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-07-30
Primary completion
2024-06-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
HS-10380

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead Sponsor

Sites

0 total

Linked catalysts

1
Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patient — primary completion2024-06-30

Facts & assertions

4 sourced
Enrollment
112
Phase
PHASE1,PHASE2
Primary Completion Date
2024-06-30
Status
UNKNOWN
relationships
The graph out of here
drug
HS-10380
drug
lead_sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication